Confronting the everchanging epidemiology
of IMD: The value of meningococcal
vaccination in the paediatric population
08 Dec 2020
At the Nimenrix Speaker Training Workshop webinar, Dr Amgad Gamil of Pfizer Inc. discussed updates on the epidemiology of invasive meningococcal disease (IMD), while simultaneously reviewing the latest immunogenicity and safety data of the MenACWY-TT vaccine (Nimenrix®, Pfizer) in the paediatric population.
Related MIMS Drugs